David Tottori, MD
Allergy · Las Vegas, NVNPI 1245284546
Payments from drug & device makers
Across 597 payments — averaging $106.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$48K
- Genentech USA, Inc.$5K
- Regeneron Healthcare Solutions, Inc.$3K
- Amgen$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Novartis$615
- plus $3K from 26 others
What the payments were for
- Consulting fees$5,8659%
- Speaking & faculty fees$45,13071%
- Food & beverage$12,02819%
- Education$5771%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 251 | $48,023 |
| Genentech USA, Inc. | 37 | $5,011 |
| Regeneron Healthcare Solutions, Inc. | 60 | $3,116 |
| Amgen(2 entities) | 75 | $2,448 |
| Teva Pharmaceuticals USA, Inc. | 9 | $1,818 |
| Novartis | 36 | $615 |
| LEO Pharma Inc. | 24 | $451 |
| Pfizer | 28 | $426 |
| Sanofi | 19 | $367 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $330 |
| CSL Behring | 6 | $149 |
| Mylan Specialty L.p. | 6 | $119 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Medtronic | 1 | $81 |
| Arcutis Biotherapeutics, Inc. | 4 | $76 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $59 |
| Boehringer Ingelheim | 2 | $41 |
| Organon | 2 | $39 |
| Genentech, Inc. | 1 | $38 |
| Biocryst US Sales Co., LLC | 2 | $35 |
| Shire North American Group Inc | 2 | $34 |
| Verona Pharma, Inc. | 1 | $30 |
| Covis Pharma GmbH | 2 | $28 |
| Kaleo, Inc. | 2 | $28 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Dermavant Sciences, Inc. | 1 | $20 |
| AbbVie | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
| Biocryst Pharmaceuticals, Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$23,170
- TEZSPIRE$11,677
- AIRSUPRA$8,138
- XOLAIR$4,615
- DUPIXENT$2,136
- BREZTRI$1,875
- ArmonAir Digihaler$1,680
- AirDuo RespiClick$1,680
- ProAir Digihaler$1,680
- SYMBICORT$818
- FARXIGA$818
- SAPHNELO$530
How this compares
Too few allergy providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 356 | $1,107,687 |
| Dupixent SyringeDupilumab | 159 | $649,525 |
| TezspireTezepelumab-Ekko | 99 | $411,197 |
| FasenraBenralizumab | 64 | $379,435 |
| Breo ElliptaFluticasone/Vilanterol | 221 | $103,815 |
| Dupixent PenDupilumab | 26 | $101,409 |
| Epinephrine | 321 | $61,777 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $58,277 |
| SymbicortBudesonide/Formoterol Fumarate | 136 | $40,571 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 216 | $37,108 |
| Spiriva RespimatTiotropium Bromide | 60 | $36,247 |
| Arnuity ElliptaFluticasone Furoate | 113 | $30,618 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $23,292 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 751 | $21,932 |
| Azelastine Hcl | 639 | $16,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $38 | $1,107,687356 claims |
| AstraZenecaTezspire, Fasenra, Symbicort, Breztri Aerosphere | $48,023 | $854,496334 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $61,777321 claims |
| Boehringer IngelheimSpiriva Respimat | $41 | $36,24760 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $1,818 | $2,99312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other allergy in Las Vegas
- Simhean LeeLas Vegas$8K
- Carol BarlowLas Vegas$14
- Maria ReyesReno$5K
- Boris LokshinSparks$4K
- Leonard ShapiroSparks$543
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.